July 7, 2023Recently, Beilu Pharmaceutical received the Drug Registration Certificate for two sizes (0.375mg and 0.75mg) of Pramipexole Dihydrochloride Sustained-release Tablets (Pramipexole) from the National Me...view
May 29, 2023Beijing Beilu Pharmaceutical Co., Ltd invites youto participate in the 2023 World Life Science Conference and Beijing International Life and Health Industry Cross-border ExpoBooth Number: 1B210Exhibit...view
September 7, 2022Taking the "Top 100 Chinese Pharmaceutical Enterprises" as the medium and long-term goal, Beilu Pharma has decided to choose not only the Contrast Agent field, Central Nervous System (Propri...view
December 1, 2023The flagship product, Jiuwei Zhenxin Granules, a central nervous system medication developed by Beilu Pharmaceutical, has been included in the "Guidelines for the Diagnosis and Treatment of Ankyl...view
December 27, 2022In order to further expand overseas markets and meet the needs of the company's strategic development, Beilu Pharmaceutical intends to establish a wholly-owned subsidiary in Hong Kong.Actively exp...view
August 4, 2022Recently, the Beijing Municipal Drug Administration and Beijing Municipal Health Commission issued the "notice on the outstanding Performance of units and individuals in the monitoring of adverse...view